POZ - Treatment News : Gold Nanoparticles Revive HIV Drug’s Prospects
Subscribe to:
POZ magazine E-newsletters
POZ Personals Sign In / Join
Username:
Password:

Back to home » Treatment News » May 2008

Web Exclusives

Wafaa El-Sadr: A “Genius” AIDS Research Pioneer

Looking Back, Moving Forward: Reflections on USCA

Claudia Medina: Fighting for Latino People With HIV

» More

Most Talked About

A 'Functional' Cure for HIV? (17)

Only Took Me 23 Years... (blog) (15)

The State of AIDS in Puerto Rico (13)

Politicians Urge Bush for Final Repeal of HIV Travel Ban (11)

HIV-Positive People Living Longer Than Ever Before (10)

TGI Friday’s Fined for Firing HIV-Positive Employee (9)

What's That Mean?
(just double-click it!)

NEW! If you don't understand one of the words in this article, just double-click it. A window will open with a definition from CancerWEB's On-line Medical Dictionary. If the double-click feature doesn't work in your browser, you can enter the word below:


Most Popular Lessons

The HIV Life Cycle

Herpes Simplex Virus

Human Papilloma Virus (HPV)

Shingles

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

10 Years Ago In POZ


More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.


emailrssprint

May 27, 2008

Gold Nanoparticles Revive HIV Drug’s Prospects

Adding minuscule bits of gold, called nanoparticles, to a failed HIV drug causes it to work much better without creating dangerous side effects, say the authors of a study published online on May 13 in the Journal of the American Chemical Society and reported by ScienceDaily.

Takeda Pharmaceuticals’ TAK-779 is an entry inhibitor that was designed to bind to the CCR5 receptor on the surface of CD4 cells. HIV uses this receptor to enter and infect CD4 cells. For TAK-779 to work properly, it requires an aluminum salt molecule. This molecule, however, was found to cause side effects. Because the drug doesn’t work without the molecule, its development was halted indefinitely.

Christian Melander, PhD, from the University of North Carolina, Chapel Hill, and his colleagues questioned whether adding gold nanoparticles in place of the salt molecule might allow TAK-779 to work without adding side effects. When Melander’s team joined a fragment of the drug to a gold nanoparticle, they found that the combo was able to shut down HIV reproduction in test-tube studies.

Because the human body does not react negatively to gold, Melander’s team believes that the new version of TAK-779 bound to gold nanoparticles shouldn’t have significant side effects. “We've discovered a non-harmful way to improve the strength and efficacy of an important drug,” Melander says. “There’s no reason to think that this same process can’t be used with similar effect on other existing drugs.”

In fact, researchers from Tibotec and other companies are actively exploring ways to use nanoparticles to create versions of both approved and experimental HIV drugs that may only need to be taken once a month or even less often.

Search: gold, nanoparticles, Takeda, TAK-779, Christian Melander, University of North Carolina


Scroll down to comment on this story.

emailrssprint


Name: (2-50 characters)
Email: (will not show)
City: (optional)

Comment (500 characters left):

(Note: The POZ team review all comments before they are posted. Please do not include either ":" or "@" in your comment.)

| Posting Rules

Previous Comments:

         


[Go to top]

Get Started
Get Answers
What to do if you've just been diagnosed
How to find a support system
Things you should know before starting treatment
How to handle side effects and other concerns
How to tell someone you have HIV/AIDS

Talk to Us
Weekly Poll
Question: Have you ever been tested for TB?
Yes
No

Monthly Poll
Question: Do you think the new American president will effectively address HIV/AIDS issues during his first 100 days?
Yes
No
I don't know

Surveys
Tell us about your travel experiences.

Tell us about your pets.

more surveys  
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertise/contact us | site map]
© 2008 Smart + Strong. All Rights Reserved. Terms of use and Your privacy